Losigamone

Losigamone (AO-33) is an orally active antiepileptic compound. Losigamone blocks sodium channel. Losigamone stimulates the neuronal chloride channel and enhance chloride influx. Losigamone potentiates GABA-mediated responses and reduces epileptiform activity induced by chloride channel antagonists. Losigamone can be used for epilepsy research[1][2].

Product Specifications

CAS Number

[112856-44-7]

Product Name Alternative

AO-33; (±) -Losigamone; LSG

UNSPSC

12352005

Target

Chloride Channel; Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/losigamone.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O[C@H](C1=C(C=CC=C1)Cl)[C@@]2([H])C(OC)=CC(O2)=O

Molecular Formula

C12H11ClO4

Molecular Weight

254.67

References & Citations

[1]Chen H, et al. Losigamone add-on therapy for focal epilepsy. Cochrane Database Syst Rev. 2019 Dec 11;12 (12) :CD009324.|[2]Jones FA, et al. The anticonvulsant effects of the enantiomers of losigamone. Br J Pharmacol. 1999 Nov;128 (6) :1223-8.